Thomas M. Beck, MD; Arthur A. Ciociola, PhD; Stephen E. Jones, MD; Walter H. Harvey, DO; N. Simon Tchekmedyian, MD; Alex Chang, MD; Daniel Galvin, MS; Nan E. Hart, BA; Ondansetron Study Group*
To evaluate the efficacy and safety of oral ondansetron (Zofran) as an antiemetic in patients receiving cyclophosphamide-based chemotherapy.
A multicenter, randomized, double-blind, stratified, placebo-controlled trial conducted between March 1989 and January 1990.
Twenty-seven oncology centers including university hospitals, community cancer centers, and private medical oncology practices.
A total of 349 chemotherapy-naive patients having their first cycle of cyclophosphamide (≥ 450 mg/m2)-based chemotherapy. Patients also received methotrexate (≥ 30 mg/m2) or doxorubicin (≥ 35 mg/m2). All patients were evaluated for safety and 318 (91%) were evaluated for efficacy.
Patients were randomly assigned to one of four treatment groups: placebo, 1 mg, 4 mg, or 8 mg of ondansetron. Assigned study medication was taken three times per day for 3 consecutive days.
Time and number of emetic episodes as well as degree of nausea were recorded by patients for each of the 3 study days.
Compared with placebo, all three doses of ondansetron were superior (P < 0.001) in preventing vomiting and controlling nausea. A complete response (no emetic episodes) was observed in 19%, 57%, 65%, and 66% of patients in the placebo, 1-mg, 4-mg, and 8-mg ondansetron groups, respectively. For patients who received higher-dose cyclophosphamide and doxorubicin, a dose-related trend in antiemetic efficacy of ondansetron was observed. Mild headache and constipation were the most frequently reported adverse events. No extrapyramidal reactions were observed.
Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy.
* For current author addresses and the members of the study group, see end of text.
Beck TM, Ciociola AA, Jones SE, et al, Ondansetron Study Group*. Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy. Ann Intern Med. 1993;118:407–413. doi: https://doi.org/10.7326/0003-4819-118-6-199303150-00002
Download citation file:
Published: Ann Intern Med. 1993;118(6):407-413.
Gastroenterology/Hepatology, Hematology/Oncology, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use